Expert

The Challenging Behaviors of Alzheimer's Disease: Other Treatment Options (Part Three)

Swank Memory Care Center, Christiana Care Health System
Tuesday, October 10, 2017
Doctor talking with his patient.

This final installment of a three-part series explores some of the non-antipsychotic treatment options to help manage the challenging behaviors of Alzheimer’s disease. Some of these involve medications, while others are psychosocial interventions.

In part one of this three-part discussion of challenging behavioral symptoms in Major Neurocognitive Disorder (previously called “dementia” and abbreviated here as MaND), we explored the range of non-cognitive behavioral disturbances that complicate the care of a person with MaND. In part two, we looked in depth at the controversy surrounding the use of antipsychotic medications in the treatment of these behaviors. In this final installment of the series, we will look at some of the non-antipsychotic treatment approaches. Some of these involve medications or electroconvulsive therapy, while others are psychosocial. We will also describe a newly publicized approach to the management of challenging behaviors.

FDA Approved Drugs

The Food and Drug Administration (FDA) has given two classes of medication approval (“indication”) for the treatment of Alzheimer’s disease. The cholinesterase inhibitor class has multiple members: tacrine (Cognex) is no longer in use while donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne) are used widely. The other class of medications, antagonists of the NMDA glutamate receptor, contains only one member: memantine (Namenda). Although the medications from these two groups have different mechanisms of action and different side effects, they share important clinical features. All of these medications are considered to be symptomatic treatments rather than significantly disease-modifying agents. Each has been shown to improve cognition modestly, and to have mild beneficial effects on activities of daily living and caregiver burden. Neither the cholinesterase inhibitors nor memantine, however, has been shown convincingly to have beneficial effects on established challenging behaviors such as agitation, insomnia, or wandering.

Off-Label Treatments

Anticonvulsants

Anticonvulsants, another class of medications with both powerful effects and significant potential adverse effects, have been used off-label in the treatment of challenging dementia behaviors. The data for their efficacy is most complete for divalproex (Depakote), which is the more frequently used of these medications for this purpose. Unfortunately, the use of divalproex as a treatment for challenging behaviors, though sometimes effective, is not well-supported by the evidence. Another anticonvulsant, carbamazepine (Tegretol), has a very limited but more consistently positive evidence base. Perhaps it should be used more frequently, but its adverse effects and interactions with other drugs have rendered it less popular. Lamotrigine (Lamictal), gabapentin (Neurontin), topiramate (Topamax), and oxcarbazepine (Trileptal) have all been tried and supported by small case studies or anecdotal successes, but support for their use is very limited.

Antianxiety Medications

Medications, called benzodiazepines, such as lorazepam (Ativan), alprazolam (Xanax), oxazepam (Serax), or clonazepam (Klonopin) are sometimes prescribed off-label in the effort to reduce agitation in people with dementia. A handful of studies in which these medications have been compared to antipsychotics such as thioridazine (Mellaril, no longer available) or haloperidol (Haldol) found similar efficacy, but the efficacy of both classes is limited. Furthermore, the adverse effects of benzodiazepines in older adults with cognitive impairment can be quite problematic: gait instability, increased falls, unwanted sedation, and confusion. In a small number of people with dementia who require medication treatment and are intolerant of other options, the benzodiazepines may play a reasonable role but their use should be minimal. Dosage and duration of treatment should be restricted to what is required, and there should be attentive monitoring of efficacy and adverse effects.

Antidepressants

In contrast to these other medication classes, there is considerable interest in the potential benefits of treatment for challenging behaviors with off-label use of some members of the antidepressant class. Citalopram, according to an FDA warning, is not intended for use above 20 mg/d (milligrams per day) in elderly patients as a result of evidence of cardiac conduction problems associated with higher doses. Cardiac conduction refers to special cells in the heart that send signals to the heart muscle causing it to contract. Escitalopram (Lexapro), which is a chemical relative of citalopram, appears to have a milder but still potentially significant risk for cardiac conduction issues. Other members of the SSRI (selective serotonin reuptake inhibitor) antidepressant class such as sertraline (Zoloft) have not been shown to impact cardiac conduction to the same degree and would be preferred in a patient at risk for conduction-related arrhythmias (heart rhythm abnormalities).

Treatment Options for Extreme Cases

In some cases, dementia-related behaviors create danger for the patient and caregiver that must be controlled in order to achieve safety even if this requires off-label use of a medication with potentially severe adverse effects. Although less fully studied, some disruptive behaviors in people with dementia have been controlled through the use of adrenergic blockers, e.g. prazosin (Minipress); synthetic tetrahydrocannabinol or dronabinol (Marinol); and testosterone blockers such as cyproterone (Androcur). Pain relievers including opiates have also been explored in this role. Increasing public concern about opiate misuse, however, would be a relative contraindication for the use of one of these stronger pain relievers. The safe and appropriate use of these more extreme agents, as well as that of electroconvulsive therapy (ECT), are mentioned here but will not be reviewed in any depth, though each approach has been supported by appropriate research data.

Non-Medication Alternatives

As indicated in the earlier sections of this series, medications are by no means the only way to address challenging behaviors in dementia. In fact, patients, caregivers, clinicians, and advocacy organizations have all expressed concern about the overuse of psychotropic drugs in nursing homes. The Center for Medicare and Medicaid Services (CMS) reported data in 2011 indicating that 83% of claims for antipsychotic medications given to elderly nursing home residents were associated with off label use, meaning prescribed for an unapproved indication, age group, dosage, or form of administration.

Behavioral Interventions

Behavioral interventions have done as well as medications in some studies and lack the potentially harmful adverse effects of medications. Among the non-medication behavioral interventions available to caregivers in institutional and home settings, some of the most effective techniques are distraction, redirection, massage, music therapy, physical activity, aromatherapy, and simulated presence therapy.

Innovative new programs such as the Eden Alternative have espoused an approach to dementia treatment described as drug-free and person-centered. In Vermont, a treatment approach named the Oasis Program was developed with the goal of transforming dementia care in nursing homes and reducing inappropriate antipsychotic medication usage by focusing on prevention rather than intervention for behavioral issues.

The “DICE” Model

Pulling both physical and psychosocial approaches together into a cleverly organized mnemonic, Dr. Helen Kales and her colleagues (JAGS 2014;61:762-9) have described the “DICE” model for intervention with challenging behaviors in people with dementia.

  • “D” reminds us to “describe” a disruptive behavior. What is it? When does it occur and with whom? What is the patient perspective on the behavior? How much distress does it cause patient and caregiver?
  • “I” reminds us to “investigate” the causes of the behavior. Is it an indicator of unrecognized pain, frustration, fear, or boredom? Does it represent medication side effects or an undiscovered medical or psychiatric condition? Is it the result of sensory changes and functional limitations? Does it represent an inappropriate caregiver expectation or a cultural issue?
  • “C” reminds us to “create” an intervention that addresses the behavior directly. This may include diagnosing and treating pain-inducing physical conditions such as constipation, using a behavioral analysis to craft a behavioral treatment plan, supporting the caregivers, simplifying tasks, finding meaningful activities, or increasing/decreasing stimulation in the environment. Individualized music therapy, for example, can take into account a person’s musical preference and provides soothing music through headphones and an MP3 player. When appropriate, the created intervention may include use of an appropriately chosen and monitored medication.
  • Finally, the very important “E” reminds us to “evaluate” the effect of the intervention, noting whether it has helped and also whether there have also been unintended consequences or side effects of the intervention.

Summary

Management of challenging behaviors in persons with dementia represents one of the most important objectives of dementia care. For patients and caregivers, these behaviors are the most difficult aspect of care. With better prevention and control, people with dementia will be able to remain in less restrictive treatment settings, impose less burden on their caregivers, and sustain a higher quality of life for a longer time.

The information provided here is a public service of the BrightFocus Foundation and should not in any way substitute for personalized advice of a qualified healthcare professional; it is not intended to constitute medical advice. Please consult your physician for personalized medical advice. BrightFocus Foundation does not endorse any medical product, therapy, or resources mentioned or listed in this article. All medications and supplements should only be taken under medical supervision. Also, although we make every effort to keep the medical information on our website updated, we cannot guarantee that the posted information reflects the most up-to-date research.

These articles do not imply an endorsement of BrightFocus by the author or their institution, nor do they imply an endorsement of the institution or author by BrightFocus.

Some of the content may be adapted from other sources, which will be clearly identified within the article.

More Like This

  • Woman with Early-Onset Alzheimer's Disease
    Expert

    Early-Onset Alzheimer’s Disease

    Learn about the key differences between the early and late onset forms of Alzheimer’s disease.

    Wednesday, October 11, 2017
  • Doctor reviewig medical records with a patient.
    Expert

    Clinical Trials for Alzheimer’s Disease: What’s New?

    Not since 2003 has a new medication been approved by the FDA for treatment of Alzheimer’s disease (AD). Fortunately, this long dry spell may be nearing an end. This article explores a variety of clinical trials that may one day provide new treatments and methods to more effectively manage Alzheimer’s disease.

    Tuesday, October 10, 2017

Don't miss out.
Receive research updates, inspiring stories, and expert advice
Keep me imformed about: *
Please select at least one.
You must select at least one disease category.
Please enter your first name.
Please enter your last name.